Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Vestre Viken HF
Sponsor

Vestre Viken HF

Norway Groenland 32, 3045 Drammen, Norway

About the sponsor

Clinical research at Vestre Viken HF includes treatment of EGFR-mutated non-small cell lung cancer, with interest in first-line targeted therapy and associated biological sampling.

  • Osimertinib
  • Objective response rate
  • Biological samples

The focus reflects active involvement in molecularly defined lung cancer care in the advanced oncology setting.

About Specializations

Vestre Viken HF runs clinical trials in conditions such as Non-small cell lung cancer, Coronary artery disease, EGFR gene mutation, Perioperative analgesia, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Coronary artery disease

Not yet recruiting

Continuing vs Stopping Acetylsalicylic Acid in Elderly Patients with Chronic Coronary Syndrome (Secondary Prevention): A Randomized Trial

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Vestre Viken HF

EGFR gene mutation+1

Not recruiting

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Vestre Viken HF

Perioperative analgesia

Not recruiting

Study on the Emotional Effects of Morphine, Oxycodone, and Fentanyl Before Surgery in Healthy or Mildly Ill Patients

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Fentanyl
  • Sponsor:Vestre Viken HF

K-ras gene mutation+2

Not recruiting

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sotorasib
  • Sponsor:Vestre Viken HF

Non-small cell lung cancer+1

Not recruiting

Study on the Effectiveness and Safety of UV1 Vaccine with or without Sargramostim for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Vestre Viken HF

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.